IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Johansson et al

Serial No. 09/050,366

Filed: March 31, 1998

Use of Growth Hormone For:

Art Unit: 1654

Examiner: Moezie, F.

Atty Docket: 0151/00211



FORM PTO-1083

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Transmitted herewith is an Amendment in the above-captioned U.S. patent application.

Small entity status of this application under 37 CFR §§ 1.9 and 1.27 has been established by a verified Π statement previously submitted.

A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed. Π

(Col 1)

(Col 2)

(Col 3)

[] SMALL ENTITY

[] NON-SMALL **ENTITY**

	CLAIMS AFTER AMDT		HIGHEST # PREVIOUSLY PAID FOR	NOW PRESENTING EXTRA
TOTAL	22	minus	20	2
INDEP		minus	2	0

RATE	ADDITIONAL FEE NOW DUE
x\$9=	\$
x\$39=	\$
+\$130	\$
TOTAL	\$

ADDITIONAL FEE NOW DUE
\$36
\$
\$
\$36

A check in the amount of \$146, including the above-indicated TOTAL amount is attached. [xx]

If extensions of time under 37 CFR § 1.136 other than those provided herewith are required to allow consideration of papers accompanying this Form PTO-1083, then such extensions of time are hereby [XX]petitioned. The Commissioner is hereby authorized to charge deficiency of payment of the following fees associated with this communication, or credit any overpayment, to Deposit Account No. 22-0185. A duplicate copy of this sheet is attached.

Any fees under 37 CFR § 1.16 for net addition of claims.

[<u>XX]</u>	Any patent application processing fees under 37 CFR § 1.17. Other:
	Respectfully submitted) Burton A! Amernick

Pollock, Vande Sande & Amernick, R.L.L.P.

1990 M Street, N.W.

Washington, D. C. 20036-3425 Telephone: 202-331-7111

Date: